Effects of Oxymatrine on the Proliferation of Human Liver Cancer Bel-7404 Cells: A Protocol of Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Jun 6

PMID 32501970

Authors

Jing Li

Zhi-Ye Liu

Hai-Bo Yu

Qing Xue

Xiu-Sheng Qu

Affiliations

Soon will be listed here.

Abstract

Background: This study will examine the effects of oxymatrine on the proliferation of human liver cancer Bel-7404 cells (HLCBC).

Methods: This study will search electronic bibliographic databases available in PUBMED, EMBASE, Cochrane Library, Scopus, Cumulative Index to Nursing and Allied Health Literature, China Biology Medicine, and China National Knowledge Infrastructure. We attempt to search case-controlled studies (CCSs) or randomized controlled studies (RCSs) pertaining to HLCBC from their inception to the February 29, 2020 without limitations of language and publication time. We will include any CCSs or RCSs on exploring oxymatrine on the proliferation of HLCBC. We will assess the methodological quality of CCSs by Newcastle-Ottawa Scale, and RCSs by Cochrane risk of bias tool. Review Manager 5.3 software will be utilized for statistical analysis.

Results: The current study will summarize most recent eligible studies to investigate the effects of oxymatrine on the proliferation of HLCBC.

Conclusion: Its results may provide reliable scientific evidence on effects of oxymatrine on the proliferation of HLCBC.

Systematic Review Registration: INPLASY202040026.

References

Jindal A, Thadi A, Shailubhai K . Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol. 2019; 9(2):221-232. PMC: 6477125. DOI: 10.1016/j.jceh.2019.01.004. View

Fabregat I, Roncero C, Fernandez M . Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007; 27(2):155-62. DOI: 10.1111/j.1478-3231.2006.01409.x. View

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

Cheng S, Chen M, Cai J . Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2016; 8(5):8867-8876. PMC: 5352449. DOI: 10.18632/oncotarget.12817. View

Hartke J, Johnson M, Ghabril M . The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017; 34(2):153-159. DOI: 10.1053/j.semdp.2016.12.011. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Attwa M, El-Etreby S . Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015; 7(12):1632-51. PMC: 4483545. DOI: 10.4254/wjh.v7.i12.1632. View

10.

Singal A, Lampertico P, Nahon P . Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72(2):250-261. PMC: 6986771. DOI: 10.1016/j.jhep.2019.08.025. View

11.

Sherman M, Colombo M . Hepatocellular carcinoma screening and diagnosis. Semin Liver Dis. 2014; 34(4):389-97. DOI: 10.1055/s-0034-1394139. View

12.

Spangenberg H, Thimme R, Blum H . Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2008; 2(3):425-33. DOI: 10.1586/17474124.2.3.425. View

13.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

14.

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

15.

Li Z, Zhu J . Hepatocellular carcinoma: Current situation and challenge. Hepatobiliary Pancreat Dis Int. 2019; 18(4):303-304. DOI: 10.1016/j.hbpd.2019.05.013. View

16.

Sherman M . Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010; 30(1):3-16. DOI: 10.1055/s-0030-1247128. View

17.

Guicciardi M, Gores G . Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005; 54(7):1024-33. PMC: 1774601. DOI: 10.1136/gut.2004.053850. View